Publications by authors named "Retesh Kumar"

Claim this Profile
S
Safety Reporting for Auxiliary Medicinal Products in the Sibeprenlimab Phase-III Study According to the New European Union (536/2014) CT Regulation.
Retesh Kumar, Pratyush Giri, Mai Huang, Nipa Parikh, Vikalp Khare

Curr Drug Saf· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver safety of tolvaptan in patients with autosomal dominant polycystic kidney disease: interim data from a post-authorization safety study.
Thomas Jaeger, Emanuel Lohrmann, Adachukwu Ezenekwe, Kene Enekebe, Retesh Kumar

Clin Kidney J· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolvaptan and Number Needed to Harm in Autosomal Dominant Polycystic Kidney Disease.
Keith A Betts, Sasikiran Nunna, Retesh Kumar, Xiaoyu Nie, Ancilla W Fernandes

Kidney Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing the Efficiency of the Individual Case Safety Report (ICSR) Quality and Compliance through Automation.
Shannon Link, Adam Kammler, Ritu Gupta, Mahendra Hembade, Retesh Kumar

Curr Drug Saf· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International Variability in the Epidemiology, Management, and Outcomes of CKD and ESKD: A Systematic Review.
Daniel E Freedberg, Leslie Segall, Benjamin Liu, Judith S Jacobson, Sumit Mohan, Retesh Kumar

Kidney360· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis